1.	Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CDR0000067047, SPRI-C/I98-102, SPRI-C98-102, NCI-V99-1544, NCT00003880
2.	Phase II Study of SCH 58500 Plus Combination Chemotherapy in Patients with Non-Small Cell Lung Cancer (Summary Last Modified 11/98) Phase: Phase II Type: Treatment Status: Closed Age: 18 to 74 Sponsor: Pharmaceutical / Industry Protocol IDs: SPRI-C/I97-076
3.	Phase I Study of Gene Therapy With SCH-58500 (rAd/p53) Via Hepatic Artery Infusion in Patients With Primary and Metastatic Malignant Tumors of the Liver (Summary Last Modified 07/2000) Phase: Phase I Type: Treatment Status: Closed Age: 18 to 74 Sponsor: Pharmaceutical / Industry Protocol IDs: SPRI-C95-063-01, NCI-V97-1179
4.	Phase I Study in Patients with Cutaneous or Subcutaneous, Recurrent Breast Carcinoma or Melanoma Using SCH-58500 (rAd/p53) Administered by Single Intratumoral Dose (Summary Last Modified 08/97) Phase: Phase I Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: SPRI-I/C95-082-01, NCI-V97-1180
5.	SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CDR0000065438, SPRI-I/C95-084, NCI-V97-1181, NCT00002960
6.	Phase I Study of SCH-58500 (rAd/p53) Administered by Single Intratumoral Injection for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (Summary Last Modified 12/98) Phase: Phase I Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: SPRI-I/C95-177-01, NCI-V97-1182
7.	Phase I Study of SCH-58500 (rAd/p53) Administered by Single Intratumoral Injection in Patients With Non-Small Cell Lung Cancer (Summary Last Modified 12/97) Phase: Phase I Type: Treatment Status: Completed Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: SPRI-I95-178-02, NCI-V97-1186
8.	Phase I Study of SCH-58500 (Adenoviral p53 Gene Therapy) in Patients with Recurrent or Progressive Resectable Glioblastoma Multiforme, Anaplastic Astrocytoma, or Anaplastic Mixed Glioma Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NABTT-9703, JHOC-NABTT-9703, NCT00004080